StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a report released on Monday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Trading Down 5.9 %
Pulmatrix stock opened at $1.89 on Monday. Pulmatrix has a 12 month low of $1.55 and a 12 month high of $3.14. The stock’s 50 day simple moving average is $1.80 and its two-hundred day simple moving average is $1.88. The firm has a market cap of $6.90 million, a PE ratio of -0.49 and a beta of 0.92.
Institutional Investors Weigh In On Pulmatrix
Several hedge funds have recently bought and sold shares of PULM. Renaissance Technologies LLC raised its stake in shares of Pulmatrix by 7.3% during the 2nd quarter. Renaissance Technologies LLC now owns 121,920 shares of the biotechnology company’s stock worth $560,000 after buying an additional 8,300 shares during the period. Vanguard Group Inc. raised its stake in Pulmatrix by 62.9% in the 4th quarter. Vanguard Group Inc. now owns 35,082 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 13,548 shares during the last quarter. Susquehanna International Group LLP acquired a new position in Pulmatrix in the 1st quarter valued at $73,000. Mariner LLC acquired a new position in Pulmatrix in the 4th quarter valued at $97,000. Finally, Citadel Advisors LLC acquired a new position in Pulmatrix in the 2nd quarter valued at $141,000. Hedge funds and other institutional investors own 11.84% of the company’s stock.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Further Reading
- Five stocks we like better than Pulmatrix
- Canada Bond Market Holiday: How to Invest and Trade
- Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- The 5 Hottest CEO Stock Purchases So Far This Year
- The How and Why of Investing in Biotech Stocks
- Institutions Think This Consumer Stock Could Break Higher
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
